Does Ozempic Cause Bone Loss? What the Research Actually Shows

Who Is Most at Risk

Not everyone taking GLP-1 medications will experience clinically meaningful bone density loss. The risk is significantly higher for specific groups, and understanding whether you fall into one of them determines how aggressively you should be managing bone protection from the start of treatment.

• Postmenopausal women. Oestrogen plays a critical role in maintaining bone density, and its decline after menopause accelerates natural bone loss. Adding the mechanical unloading and nutritional effects of GLP-1 therapy to an already compromised baseline is the highest-risk combination. The Wegovy FDA label specifically notes higher fracture rates in women: 1% vs 0.2% in the placebo group.
• Adults over 65. Natural age-related bone loss is 1–2% per year after 50. Adding GLP-1-associated loss to this background rate means cumulative reductions that may cross the fracture threshold more quickly.
• People losing weight rapidly. The dose-response relationship between weight loss and bone loss is now clear — greater weight loss means greater bone loss. Anyone losing more than 0.5–1kg per week sustained over months should be treating bone protection as a priority.
• People with pre-existing osteopenia or osteoporosis. The Endocrine Society study found 75% of its high-fracture-risk cohort already had osteopenia or osteoporosis at baseline. Starting from a compromised position amplifies the clinical impact of any further decline.
• People on tirzepatide (Mounjaro, Zepbound). The TriNetX study found a 44% higher risk of osteoporosis or fragility fracture with tirzepatide vs other GLP-1 medications. Greater weight loss = greater bone exposure risk.
• People with inadequate calcium, vitamin D, or protein intake. Appetite suppression that is not managed with deliberate nutritional strategy will result in deficiencies in all three nutrients, directly accelerating bone loss independent of the mechanical unloading effect.
• People who are not resistance training. The JAMA Network Open exercise study makes the protective effect of resistance training against GLP-1-associated bone loss as close to proven as observational evidence gets. Not resistance training while on GLP-1 therapy removes the most powerful protective tool available.

Why GLP-1 Therapy Affects Bone Density

Understanding the mechanism is important because it clarifies what can be done about it. The bone loss associated with GLP-1 therapy does not appear to result from a direct pharmacological effect of the drugs on bone tissue. It appears to result from two interconnected consequences of the weight loss the medications produce.

Reduced mechanical load on the skeleton

Bone is a dynamic tissue that constantly remodels itself in response to the physical demands placed on it. When you carry more body weight, your skeleton experiences more mechanical load, and bone formation is stimulated to meet that demand. When weight drops rapidly — as it does on GLP-1 therapy, where 15–21% total body weight reductions are documented in clinical trials — the mechanical load on bones decreases significantly. The skeleton responds by reducing bone formation, because it no longer needs to maintain the bone mass it had at a higher weight. This is not a new phenomenon unique to GLP-1 medications. The same effect is well-documented after bariatric surgery and aggressive calorie restriction.

Nutrient deficiency from appetite suppression

GLP-1 medications reduce food intake by 30–50% for most users. When overall calorie intake drops this dramatically, the intake of bone-critical nutrients — calcium, vitamin D, magnesium, and protein — typically drops with it. Calcium is the primary structural mineral in bone. Vitamin D is required for calcium absorption. Protein is required for the organic matrix that gives bone its flexibility and fracture resistance. Deficiencies in any of these nutrients accelerate the bone loss that reduced mechanical load has already initiated.

Banner Health bone specialist Rachel Patel NP summarised this clearly: losing even 10 pounds over a three-month period can lead to a decline in bone mineral density and increase fracture risk. GLP-1 medications can produce that rate of loss and sustain it over 12–24 months, making the cumulative skeletal impact meaningful.

How to Protect Your Bones on GLP-1 Therapy

The evidence for bone protection strategies is strong and consistent across the literature. These are not precautionary suggestions — they are evidence-based interventions that the research shows can meaningfully reduce or eliminate GLP-1-associated bone loss.

Strategy 1 — Resistance training (non-negotiable)

This is the single most important protective strategy, and the JAMA Network Open 2024 study proves it directly. Exercise combined with GLP-1 therapy preserved bone density at the hip, spine, and forearm. Exercise alone or GLP-1 therapy alone did not achieve this protection.

The type of exercise matters. Weight-bearing cardio — walking, jogging, dancing — provides some bone stimulus. But resistance training is far more effective for bone preservation. When muscles contract against resistance, they pull on the bones they attach to, creating the mechanical stress that stimulates osteoblast activity and bone formation. This directly counteracts the mechanical unloading effect of weight loss.

The recommendation from multiple clinical sources is resistance training at least 2–3 times per week, targeting all major muscle groups. Full-body sessions are the most time-efficient approach. The same protocol that protects muscle on GLP-1 therapy — compound movements, progressive overload, 2–3 sets of 8–12 reps — is also the most effective protocol for bone protection. These goals are aligned, not competing.

Strategy 2 — Calcium intake

The standard adult recommendation for calcium is 1,000mg per day, increasing to 1,200mg per day for women over 50 and men over 70. Because GLP-1 appetite suppression significantly reduces overall food intake, dietary calcium alone is often insufficient. Most adults on GLP-1 therapy benefit from discussing calcium supplementation with their healthcare provider, particularly postmenopausal women and older adults who are already at elevated baseline risk.

The best dietary sources of calcium that are also practical for GLP-1 users — easy to eat in small quantities — include Greek yoghurt (approximately 200mg per 200g serving), cottage cheese, milk, fortified plant milks, and canned sardines with bones. Leafy greens including kale and bok choy are reasonable sources, though their calcium is less bioavailable than dairy.

Strategy 3 — Vitamin D

Vitamin D is required for calcium absorption in the gut. Without adequate vitamin D, calcium supplementation has reduced effectiveness. The minimum recommendation is 600–800 IU per day for most adults, with higher doses — typically 800–1,000 IU — recommended for people at risk for osteoporosis or those with confirmed deficiency. A simple blood test can determine current vitamin D status before supplementation begins.

Because vitamin D is fat-soluble and most GLP-1 users are reducing their fat intake along with everything else, supplementation is often the most reliable route. Most calcium supplements now come combined with vitamin D, which is a practical approach for people who need both.

Strategy 4 — Protein prioritisation

Protein is not just a muscle nutrient. It is a bone nutrient. The organic matrix that gives bone its flexibility and prevents brittle fractures is approximately 90% collagen — a structural protein that requires adequate dietary protein to maintain. Research consistently shows that higher protein intake is associated with better bone density outcomes during calorie restriction.

The minimum protein target during GLP-1 therapy is 1.0–1.2g per kilogram of body weight per day for bone protection, rising to 1.6–2.0g/kg for people actively resistance training. Because GLP-1 appetite suppression makes hitting this target through meals alone very difficult, high-protein snacks and protein shakes distributed throughout the day are typically necessary.

Should You Get a Bone Density Scan (DEXA)?

A DEXA scan is the gold standard test for measuring bone mineral density. It takes approximately 10–20 minutes, uses minimal radiation, and provides a T-score that tells you where your bone density sits relative to a healthy young adult reference population.

A baseline DEXA before starting or early in GLP-1 therapy is recommended for people with any of the following risk factors:

• Postmenopausal status
• Age over 65 (women) or 70 (men) — or earlier if other risk factors are present
• A previous fragility fracture (a fracture from a fall from standing height or less)
• Family history of osteoporosis or hip fracture
• Long-term corticosteroid use
• Low body weight or low BMI
• Planned significant weight loss (more than 10% of body weight)

For people without these risk factors, a baseline DEXA is not routinely indicated, but follow-up monitoring becomes more important as weight loss progresses — particularly if loss exceeds 10% of total body weight or if musculoskeletal symptoms develop.

If you are in any of the higher-risk categories and have been on GLP-1 therapy for six months or more without a DEXA scan, it is worth requesting one at your next clinical appointment. Early detection of bone density changes allows time to intervene with the strategies above before loss becomes clinically significant.

What the Research Actually Shows

The bone loss question has moved from theoretical concern to documented finding over the past 18 months. Several independent studies now point in the same direction, and the data is specific enough to be useful for anyone currently on or considering GLP-1 therapy.

The AAOS population study (2025)

The most widely reported finding came from a study presented at the American Academy of Orthopaedic Surgeons annual meeting in 2025. Researchers analysed health records from nearly 150,000 adults with obesity and type 2 diabetes over a five-year period. Among people taking GLP-1 receptor agonists, approximately 4% developed osteoporosis. In the group not taking these medications, the rate was just over 3%. That translates to roughly a 30% increase in relative risk — meaningful, though the absolute numbers remain modest.

The researchers also found that osteomalacia — the softening of bones rather than their thinning — occurred at nearly twice the rate in GLP-1 users. The lead researcher noted that within the data, there was nearly a doubling of the risk of having some sort of bone mineral density issue at five years.

The Weill Cornell DXA study (February 2026)

Published in the Journal of Clinical Endocrinology and Metabolism in February 2026, this retrospective study from Weill Cornell Medical College directly measured bone mineral density changes in 255 patients using semaglutide or tirzepatide, matched against 255 controls. After a median follow-up of 17 months, the GLP-1 group achieved a median 5% weight loss. Both groups experienced declines in bone mineral density at the total hip and femoral neck — but the GLP-1 group showed greater total hip bone loss in patients without diabetes. The authors concluded that weight loss was the primary driver, with the medications associated with greater bone loss specifically in non-diabetic patients — the group experiencing the largest absolute weight reductions.

The Endocrine Society fracture study (October 2025)

A separate study of 255 patients specifically at high risk for fractures — 75% of whom already had osteopenia or osteoporosis at baseline — found significant BMD declines across all measured sites over an average 34-month follow-up: lumbar spine down 1.6%, femoral neck down 1.8%, and total hip down 2.8%. Critically, the amount of bone lost was significantly correlated with the amount of weight lost — a Pearson correlation of 0.35, p<0.001. Among this high-risk group, 13% developed a new fracture after starting GLP-1 therapy.

The tirzepatide comparison study (November 2025)

A TriNetX retrospective cohort study of over 130,000 patients with type 2 diabetes or obesity compared tirzepatide users to users of other GLP-1 medications. Tirzepatide was associated with a 44% higher risk of osteoporosis or fragility fracture compared to other GLP-1 receptor agonists, and a 61% higher rate of initiating osteoporosis treatment. The authors suggest this likely reflects tirzepatide’s more pronounced weight loss effect — patients simply lose more weight on tirzepatide, which amplifies the mechanical unloading effect on bone.

The exercise intervention study — the good news (2024)

A secondary analysis of a randomised clinical trial published in JAMA Network Open in 2024 compared three groups: exercise alone, GLP-1 therapy alone, and GLP-1 therapy combined with exercise. The finding was clear — participants who combined exercise with GLP-1 therapy preserved bone density at the hip, spine, and forearm despite significantly larger total weight loss. Those taking GLP-1 therapy without exercise experienced measurable bone density reductions. This is the most clinically important finding in the bone loss literature because it identifies a modifiable intervention that directly counters the risk.

Putting the Risk in Perspective

It is important not to let this finding override what the evidence on GLP-1 medications more broadly shows. These medications have substantial documented benefits — 20% reductions in major cardiovascular events in the SELECT trial, significant improvements in heart failure symptoms, reductions in sleep apnoea, and meaningful, sustained weight loss that improves metabolic health across dozens of markers.

The bone loss risk is real. It is also modest in absolute terms for most people — a 30% increase in relative risk sounds alarming, but it translates from a 3.1% baseline rate to approximately a 4% rate over five years. For the vast majority of GLP-1 users who are not postmenopausal, over 65, or already osteopenic, the absolute fracture risk from GLP-1 therapy is small.

What the bone loss data argues for is not stopping the medication, but managing it properly — with resistance training, adequate nutrition, and appropriate monitoring for those at higher risk. These are not burdens in addition to GLP-1 therapy. They are part of the same health strategy that makes GLP-1 therapy produce lasting results rather than temporary ones.

Bone Protection Quick Reference

Frequently Asked Questions

Research & References